Clinical Trial Update: Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial evaluating an autologous tumor-derived heat shock protein gp96 vaccine for gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• gp96 autologous tumor-derived heat shock protein vaccine (heat shock protein gp96 vaccine)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Gastric Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN